Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) and Yatsen (NYSE:YSG – Get Free Report) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.
Volatility & Risk
Dermata Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Yatsen has a beta of -1.57, meaning that its stock price is 257% less volatile than the S&P 500.
Profitability
This table compares Dermata Therapeutics and Yatsen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dermata Therapeutics | N/A | -127.91% | -105.05% |
| Yatsen | -3.04% | -4.54% | -3.49% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($5.31) | -0.22 |
| Yatsen | $614.62 million | 0.53 | -$11.56 million | ($0.21) | -16.40 |
Dermata Therapeutics has higher earnings, but lower revenue than Yatsen. Yatsen is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
8.7% of Dermata Therapeutics shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 29.0% of Yatsen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for Dermata Therapeutics and Yatsen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dermata Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Yatsen | 1 | 0 | 0 | 0 | 1.00 |
Dermata Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 754.70%. Given Dermata Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than Yatsen.
Summary
Dermata Therapeutics beats Yatsen on 8 of the 13 factors compared between the two stocks.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
About Yatsen
Yatsen Holding Limited, together with its subsidiaries, engages in the development and sale of beauty products under the Perfect Diary, Little Ondine, Pink Bear, Abby’s Choice, GalÃnic, DR.WU, Eve Lom, and EANTiM brands in the People’s Republic of China. The company offers color cosmetics for lips, eyes, and face; skin care products, including face serums and creams, eye creams, masks, toners, makeup removers, cleansers, ampoules, and anti-acne patches; and beauty tools and kits, sunscreen products, and beauty devices. It sells its products through stores and online channel. The company was formerly known as Mangrove Bay Ecommerce Holding (Cayman) and changed its name to Yatsen Holding Limited in January 2019. Yatsen Holding Limited was founded in 2016 and is headquartered in Guangzhou, China.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
